Another important clue to the role played by PI3K/Akt/mTOR signaling in conferring CSC resistance to therapeutic treatments, comes from a study which has documented that in mice medulloblastoma CD133+/nestin+ CSCs (which are located in perivascular niches), radiation activated Akt/mTOR signaling. The gene discussed is MTOR; the disease is medulloblastoma.